Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06396065 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of AK112 for NSCLC Patients
A Phase 3 study of Non-squamous Non-small Cell Lung Cancer, sponsored by Summit Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
- 20
- Study locations
NCT06396065 is a Phase 3 study of Non-squamous Non-small Cell Lung Cancer that is active but no longer recruiting, run by Summit Therapeutics. The registered enrollment target is 420 participants, above the 344-participant average among 7 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT06396065, a Phase 3 study of Non-squamous Non-small Cell Lung Cancer, is active but no longer recruiting, sponsored by Summit Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Conditions Studied
Interventions
- DRUG Placebo Injection
- DRUG AK112 Injection
Study Locations (20)
California
- CBCC Global Research - Bakersfield
- UC San Diego - La Jolla
- University of Southern California - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- UCLA Department of Medicine - Hematology/Oncology - Los Angeles
- Palo Alto Medical Foundation Research Institute - Mountain View
- Providence St. Joseph - Orange
- UC Irvine - Orange
- Sutter Cancer center - Sacramento
- UC DAVIS Comprehensive Cancer Center - Sacramento
- Sharp Memorial Hospital - San Diego
- California Pacific Medical Center - San Francisco
- Providence Medical Foundation - Santa Rosa
- Presbyterian Intercommunity Hospital - Whittier
Florida
- The Oncology Institute of Hope & Innovation - Fort Lauderdale
- University of Miami - Miami
- Florida Cancer Associates - Ocala Oncology - Ocala
- BRCR Global - Plantation
- Florida Cancer Specialists - North - St. Petersburg
Colorado
- Rocky Mountain Cancer Center - Lone Tree
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06396065
The ClinicalTrials.gov registry entry for NCT06396065 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 344-participant average among 7 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (22% higher). The listed sponsor is Summit Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-squamous Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo Injection is the first listed.
NCT06396065 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT06396065 about?
NCT06396065 is a clinical study titled "Phase III Study of AK112 for NSCLC Patients". A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kina...
What is the current status of trial NCT06396065?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2023-05-04. Estimated completion is 2026-12-31.
What conditions does trial NCT06396065 study?
This clinical trial studies the following conditions: Non-squamous Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT06396065?
The interventions under investigation include: Placebo Injection (DRUG), AK112 Injection (DRUG).
Who is sponsoring clinical trial NCT06396065?
This trial is sponsored by Summit Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06396065 being conducted?
This trial has 20 study locations across California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-squamous Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
RECRUITING · Phase 3
-
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
COMPLETED · Phase 3
-
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
COMPLETED · Phase 3
-
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.